Premium
Quantitative determination of the novel anticancer drug E7070 (indisulam) and its metabolite (1,4‐benzenedisulphonamide) in human plasma, urine and faeces by high‐performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry
Author(s) -
Beumer Jan Hendrik,
Rosing Hilde,
Hillebrand Michel J. X.,
NanOfferinga Lianda G. A. H.,
Foley Karen,
Yule S. Murray,
Heck Albert J. R.,
Schellens Jan H. M.,
Beijnen Jos H.
Publication year - 2004
Publication title -
rapid communications in mass spectrometry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.528
H-Index - 136
eISSN - 1097-0231
pISSN - 0951-4198
DOI - 10.1002/rcm.1699
Subject(s) - chemistry , chromatography , metabolite , analyte , electrospray ionization , solid phase extraction , tandem mass spectrometry , urine , extraction (chemistry) , mass spectrometry , liquid chromatography–mass spectrometry , electrospray , sample preparation , selected reaction monitoring , biochemistry
E7070 (indisulam) is a novel anticancer drug currently undergoing clinical investigation. We present a sensitive and specific method for the quantitative determination of E7070 and its metabolite M1 (1,4‐benzenedisulphonamide) in human plasma, urine and faeces. The analytes and their tetra‐deuterated analogues, which were used as internal standards, were isolated from the biological matrix by solid‐phase extraction with OASIS cartridges (0.5 mL plasma or 1 mL urine) and by liquid‐liquid extraction with ethyl acetate at pH 5 (1 mL faecal homogenate). The analytes were separated on a C8 reversed‐phase chromatographic column and analyzed using electrospray ionization and tandem mass spectrometric detection in the negative ion mode. The validated concentration ranges in plasma were 0.1–20 μg/mL for E7070 and 0.01–2 μg/mL for M1. In urine and faecal homogenate, a concentration range from 0.05–10 μg/mL or μg/g, respectively, was validated for both analytes. Validation of the plasma assay was performed according to the most recent FDA guidelines. The assay fulfilled all generally accepted requirements for linearity (r > 0.99, residuals between −8 and 10%), accuracy (−13.5 to 1.4%) and precision (all less than 11%) in the tested matrices. We investigated recovery, stability (working solutions at −20°C and at room temperature, biological matrices at −20°C, room temperature and after 3 freeze/thaw cycles; final extracts at room temperature) and robustness. All these parameters were found acceptable. This method is suited for mass balance studies or therapeutic drug monitoring, as demonstrated by a case example showing plasma concentrations and cumulative excretion of E7070 and M1 in urine and faeces. Furthermore, we show the presence of E7070 metabolites in patient urine. Copyright © 2004 John Wiley & Sons, Ltd.